The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Receptal     (2S)-N-[(1S)-1-[[(1S)-1- [[(1S)-1-[[(1S)-1...

Synonyms: Suprecur, Profact, Suprefact, Suprecur (TN), HOE-766, ...
This record was replaced with 50225.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BUSERELIN


Psychiatry related information on BUSERELIN

  • RESULTS: Buserelin acetate markedly reduced dysmenorrhea, pelvic pain, and dyspareunia during the treatment and also for the 12 subsequent months [5].
  • CONCLUSION: Even though the clinical suppression of puberty was adequate with both modes of administration, the effect of the depot preparation, in this study Suprefact Depot, was more pronounced in terms of gonadotropin suppression and less dependent on patient compliance [6].

High impact information on BUSERELIN

  • To clarify the mechanism of the antiproliferative action of the LHRH agonists, the effects of both Z and B on the incorporation of [3H]thymidine and [14C]methionine into LNCaP cells were investigated [7].
  • A similar treatment with B was without any significant effect on the proliferation of a mouse embryo fibroblast cell line (Swiss 3T3), which was used as a nontumoral control [7].
  • Treatment had included buserelin acetate, human menopausal gonadotrophin to stimulate follicular growth and human chorionic gonadotrophin to induce ovulation [8].
  • Eight patients received a single dose GnRH-agonist stimulation test (buserelin acetate test, 10 microg/kg body weight) with a 24-h follow-up (five patients underwent both tests) [9].
  • PATIENT(S): Forty women who received the long buserelin acetate treatment protocol.Transvaginal three-dimensional power Doppler ultrasound examinations before and after pituitary down-regulation [10].

Chemical compound and disease context of BUSERELIN


Biological context of BUSERELIN


Anatomical context of BUSERELIN


Associations of BUSERELIN with other chemical compounds

  • A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients [20].
  • The morphometry results showed that endometrial glandular volume 2 days after oocyte retrieval was significantly reduced after CC/hMG compared with buserelin acetate/hMG, despite the fact that histopathological dating was similar for both groups [21].
  • The study was designed to examine whether dynamic measurements of inhibin B and oestradiol following single administration of buserelin acetate were correlated with the ovarian response to stimulation in IVF [14].
  • RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression [22].
  • OBJECTIVE: To compare two gonadotropin-releasing hormone agonists (GnRH-a), buserelin acetate and leuprolide acetate [LA], used in combination with gonadotropins in ovarian stimulation for in vitro fertilization (IVF) [23].

Gene context of BUSERELIN

  • RESULTS: Our results show that danazol concentrations (10(-7) -10(-5) M), taking into account the therapeutic levels found in the plasma of treated patients, inhibited MCP-1 protein and mRNA steady-state levels in endometriotic cells, whereas buserelin acetate (0.1-10 ng/mL), a GnRH agonist, had no significant effect [24].
  • In earlier IVF programmes, subcutaneous buserelin (Suprefact, Hoechst) was initially administered three times per day (200 micrograms x 3); then twice daily (300 micrograms x 2) [25].
  • In the three experimental groups, each animal received subcutaneous injections of the long-acting GnRH agonist, buserelin acetate, once every four weeks throughout the experiment [26].
  • On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol [27].
  • Insulin-resistant (n = 26) and non-insulin-resistant women (n = 30) with PCOS underwent a total of 100 cycles of long-term down-regulation with buserelin acetate, stimulation with human recombinant FSH, and IVF or ICSI [28].

Analytical, diagnostic and therapeutic context of BUSERELIN


  1. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Chander, S., Choo, R., Danjoux, C., Morton, G., Pearse, A., Deboer, G., Szumacher, E., Loblaw, A., Cheung, P., Woo, T. Int. J. Radiat. Oncol. Biol. Phys. (2005) [Pubmed]
  2. Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. Fedele, L., Marchini, M., Bianchi, S., Baglioni, A., Zanotti, F. Fertil. Steril. (1993) [Pubmed]
  3. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment. Kawamura, N., Ito, F., Ichimura, T., Shibata, S., Umesaki, N., Ogita, S. Fertil. Steril. (1997) [Pubmed]
  4. Chronic suppression of testicular function by constant infusion of gonadotropin-releasing hormone agonist and testosterone supplementation in the bonnet monkey (Macaca radiata). Ravindranath, N., Ramesh, V., Krishnamurthy, H.N., Rao, A.J., Moudgal, R.N. Fertil. Steril. (1992) [Pubmed]
  5. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fedele, L., Bianchi, S., Bocciolone, L., Di Nola, G., Franchi, D. Fertil. Steril. (1993) [Pubmed]
  6. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Tuvemo, T., Gustafsson, J., Proos, L.A. Horm. Res. (2002) [Pubmed]
  7. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Limonta, P., Dondi, D., Moretti, R.M., Maggi, R., Motta, M. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  8. Insulin-like growth factor-I gene expression in human granulosa-lutein cells. Huang, Z.H., Clayton, P.E., Brady, G., Morris, I.D. J. Mol. Endocrinol. (1994) [Pubmed]
  9. Increase of serum leptin after short-term pulsatile GnRH administration in children with delayed puberty. Grasemann, C., Wessels, H.T., Knauer-Fischer, S., Richter-Unruh, A., Hauffa, B.P. Eur. J. Endocrinol. (2004) [Pubmed]
  10. Effect of pituitary down-regulation on the ovary before in vitro fertilization as measured using three-dimensional power Doppler ultrasound. Järvelä, I.Y., Sladkevicius, P., Kelly, S., Ojha, K., Campbell, S., Nargund, G. Fertil. Steril. (2003) [Pubmed]
  11. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Waller, K.G., Shaw, R.W. Fertil. Steril. (1993) [Pubmed]
  12. Secretory changes in preovulatory endometrium during controlled ovarian hyperstimulation with buserelin acetate and human gonadotropins. Marchini, M., Fedele, L., Bianchi, S., Losa, G.A., Ghisletta, M., Candiani, G.B. Fertil. Steril. (1991) [Pubmed]
  13. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Brinsden, P., Akagbosu, F., Gibbons, L.M., Lancaster, S., Gourdon, D., Engrand, P., Loumaye, E. Fertil. Steril. (2000) [Pubmed]
  14. Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF. Ravhon, A., Lavery, S., Michael, S., Donaldson, M., Margara, R., Trew, G., Winston, R. Hum. Reprod. (2000) [Pubmed]
  15. Predicting empty follicle syndrome. Ndukwe, G., Thornton, S., Fishel, S., Dowell, K., al-Hassan, S., Hunter, A. Fertil. Steril. (1996) [Pubmed]
  16. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Biljan, M.M., Mahutte, N.G., Dean, N., Hemmings, R., Bissonnette, F., Tan, S.L. Fertil. Steril. (1998) [Pubmed]
  17. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization. Urbancsek, J., Witthaus, E. Fertil. Steril. (1996) [Pubmed]
  18. Pregnancy rates, LH and progesterone concentrations in mares treated with a GnRH agonist. Kanitz, W., Schneider, F., Hoppen, H.O., Unger, C., N??rnberg, G., Becker, F. Anim. Reprod. Sci. (2007) [Pubmed]
  19. Postinsemination administration of receptal: follicular dynamics, duration of cycle, hormonal responses, and pregnancy rates. Stevenson, J.S., Phatak, A.P., Rettmer, I., Stewart, R.E. J. Dairy Sci. (1993) [Pubmed]
  20. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients. Polson, D.W., MacLachlan, V., Krapez, J.A., Wood, C., Healy, D.L. Fertil. Steril. (1991) [Pubmed]
  21. Correlation of endometrial histology, morphometry, and ultrasound appearance after different stimulation protocols for in vitro fertilization. Rogers, P.A., Polson, D., Murphy, C.R., Hosie, M., Susil, B., Leoni, M. Fertil. Steril. (1991) [Pubmed]
  22. Effect of hormonal agents on monocyte chemotactic protein-1 expression by endometrial epithelial cells of women with endometriosis. Boucher, A., Lemay, A., Akoum, A. Fertil. Steril. (2000) [Pubmed]
  23. The comparison of two gonadotropin-releasing hormone agonists in an in vitro fertilization program. Balasch, J., Jové, I.C., Moreno, V., Civico, S., Puerto, B., Vanrell, J.A. Fertil. Steril. (1992) [Pubmed]
  24. Comparative effect of danazol and a GnRH agonist on monocyte chemotactic protein-1 expression by endometriotic cells. Jolicoeur, C., Lemay, A., Akoum, A. Am. J. Reprod. Immunol. (2001) [Pubmed]
  25. An improved use of buserelin in ovarian stimulation for in-vitro fertilization. Belaisch-Allart, J., Allart, J.P., Dufêtre, C., Briot, P., Stalla-Bourdillon, A. Hum. Reprod. (1990) [Pubmed]
  26. Preventive effects of a herbal medicine on bone loss in rats treated with a GnRH agonist. Sakamoto, S., Sassa, S., Kudo, H., Suzuki, S., Mitamura, T., Shinoda, H. Eur. J. Endocrinol. (2000) [Pubmed]
  27. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Franssen, A.M., van der Heijden, P.F., Thomas, C.M., Doesburg, W.H., Willemsen, W.N., Rolland, R. Fertil. Steril. (1992) [Pubmed]
  28. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Fedorcsák, P., Dale, P.O., Storeng, R., Tanbo, T., Abyholm, T. Hum. Reprod. (2001) [Pubmed]
  29. First established pregnancy and birth after ovarian stimulation with recombinant human follicle stimulating hormone (Org 32489). Devroey, P., Mannaerts, B., Smitz, J., Coelingh Bennink, H., Van Steirteghem, A. Hum. Reprod. (1993) [Pubmed]
  30. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Cheung, L.P., Lam, P.M., Lok, I.H., Chiu, T.T., Yeung, S.Y., Tjer, C.C., Haines, C.J. Hum. Reprod. (2005) [Pubmed]
  31. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Takeuchi, S., Minoura, H., Shibahara, T., Tsuiki, Y., Noritaka, F., Toyoda, N. Fertil. Steril. (2001) [Pubmed]
  32. Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray. Cacciari, E., Cassio, A., Balsamo, A., Colli, C., Cicognani, A., Pirazzoli, P., Tani, G., Brondelli, L., Mandini, M., Bovicelli, L. Archives of pediatrics & adolescent medicine. (1994) [Pubmed]
WikiGenes - Universities